-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

622.O1.6 622. Lymphoma Biology—Non-Genetic Studies: Microenvironment and Immune Response in Hodgkin Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Biological, Diseases, Lymphoma (any), Hodgkin Lymphoma, Therapies, cellular interactions, Non-Hodgkin Lymphoma, Biological Processes, white blood cells, immune cells, T-Cell Lymphoma, Technology and Procedures, Cell Lineage, immunotherapy, Lymphoid Malignancies, Study Population, Clinically relevant, immune mechanism, inflammation, mass cytometry, integrative -omics, microenvironment, RNA sequencing, multi-systemic interactions, serologic tests, pathogenesis, pathways
Monday, December 7, 2020: 9:00 AM-10:30 AM
Moderators:
Anne J. Novak, PhD, Mayo Clinic and Eric D. Hsi, MD, Cleveland Clinic Foundation
Disclosures:
Novak: Celgene/BMS: Research Funding. Hsi: Eli Lilly: Research Funding; Abbvie: Research Funding; CytomX: Consultancy, Honoraria; Miltenyi: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria.
9:00 AM

Jovian Yu, MD1,2, Xiufen Chen, PhD1*, James Godfrey, MD1, Girish Venkataraman, MD, MBBS 3, Sonali M. Smith, MD4, Mengjie Chen, PhD2,5,6,7* and Justin Kline, MD1,5

1Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
2Committee on Genetics, Genomics and Systems Biology, University of Chicago, Chicago, IL
3Department of Pathology, University of Chicago, Chicago, IL
4Department of Oncology, University of Chicago, Chicago, IL
5Committee on Cancer Biology, University of Chicago, Chicago, IL
6Department of Medicine, Section of Genetic Medicine, University of Chicago, Chicago, IL
7Department of Human Genetics, University of Chicago, Chicago, IL

9:15 AM

Hema Dave1, Mimi Mai2*, Anushree Datar2*, Gaye Jenkins, BS3*, Qinglin Pei, PhD4*, Yue Wu, MS5*, Frank G. Keller, M.D.6, Sharon M. Castellino, MD, MSc7, Terzah M Horton, MD, PhD8 and Catherine M. Bollard, MD, MBChB1

1Children's National Hospital and The George Washington University, Washington, DC
2Program for Cell Enhancement and Technologies for Immunotherapy (CETI), Children's National Hospital, Washington, DC
3Baylor College of Medicine, Houston
4Children's Oncology Group Statistics & Data Center, Gainesville, FL
5Department of Biostatistics, Children's Oncology Group Statistics & Data Center, Gainesville, FL
6Pediatric Hematology/Oncology, Emory University, Atlanta, GA
7Aflac Cancer and Blood Disorders Center, Emory University School of Medicine / Children's Healthcare of Atlanta, Atlanta, GA
8Baylor College of Medicine, Houston, TX

9:30 AM

Joshua C. Pritchett, MD1, Zhi-Zhang Yang, PhD1, Hyojin Kim, PhD1*, Jose C Villasboas, MD2, Andrew L. Feldman, MD3, James R. Cerhan, MD, PhD4 and Stephen M. Ansell, MD, PhD5

1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN
2Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
4Division of Hematology, Mayo Clinic, Rochester, MN
5Mayo Clinic, Rochester, MN

*signifies non-member of ASH